The Japanese company said it had been working to get a plasma-derived treatment which had been proven to be more effective in treating acute viral respiratory ailments.
Its study might require antibodies from individuals who have recovered in the coronavirus diseases or that were vaccinated after a vaccine was developed.
“By moving the embryo to a different individual, it might help that individual’s immune system react to the disease and boost their likelihood of healing,” Takeda said in a statement.
It’s also analyzing whether its currently marketed or pipeline merchandise may be effective remedies for contaminated patients, the business said, including those attempts were in an early period.
Takeda joins other drugmakers focusing on creating drugs to deal with the flu-like disease that has struck over 90,000 people worldwide.
Pfizer Inc said on Monday it had recognized specific antibacterial chemicals it’s in development which can inhibit coronaviruses and can be participating with another party to display the chemicals.
Takeda said it could discuss its strategies with all members of the U.S. Congress on Wednesday and has been in discussions with different medical and health agencies and health care associates in the USA, Asia, and Europe to move forward its study to the medication.
The statement comes amid information that the U.S. Congress can debate and pass as soon as this week crisis financing, maybe in the assortment of $6 billion to $8 billion, to help fight the virus and assist companies.
Ahead of Takeda’s announcement, shares in the business, Japan’s most important pharmaceuticals company by market value, shut down 0.95 percent.